S. Yadavilli

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

L. Tsvetkov, J. Smothers, A. Hoos, 2015, Clinical Cancer Research.

Emergence of the CD226 Axis in Cancer Immunotherapy

J. Smothers, K. Hance, J. Waight, 2022, Frontiers in Immunology.

Immunodynamics of explanted human tumors for immuno‐oncology

L. Zitvogel, G. Kroemer, E. Fadel, 2020, EMBO molecular medicine.

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

Huiyang Zhou, L. Tsvetkov, M. Bi, 2018, PloS one.

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

J. Schellens, M. Millward, M. Maio, 2017 .

CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

K. Tarte, R. Bouabdallah, S. Granjeaud, 2018, Blood advances.

Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies

M. Bi, A. Hoos, K. Hance, 2020 .

Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody.

D. Olive, M. Cragg, M. Bi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 2268: Agonistic T cell non depleting ICOS antibody strongly enhances anti-tumor activity with CTLA4 blocking monoclonal antibody without exacerbating colitis

N. Chaput, A. Hoos, C. Coutzac, 2019, Immunology.